All Outputs (43)

Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer (2017)
Journal Article
Alexander, A., Karakas, C., Chen, X., Carey, J. P., Yi, M., Bondy, M., …Keyomarsi, K. (2017). Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. Oncotarget, 8, 14897-14911. https://doi.org/10.18632/oncotarget.14689

Inflammatory breast cancer (IBC) is a virulent form of breast cancer, and novel treatment strategies are urgently needed. Immunohistochemical analysis of tumors from women with a clinical diagnosis of IBC (n = 147) and those with non-IBC breast cance... Read More about Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer.

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial (2016)
Journal Article
Robertson, J. F., Bondarenko, I. M., Trishkina, E., Dvorkin, M., Panasci, L., Manikhas, A., …Ellis, M. J. (2016). Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet, 388(10063), 2997-3005. https://doi.org/10.1016/S0140-6736%2816%2932389-3

Background Aromatase inhibitors are a standard of care for hormone receptor-positive locally advanced or metastatic breast cancer. We investigated whether the selective oestrogen receptor degrader fulvestrant could improve progression-free surviva... Read More about Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.

Biological characteristics and clinical outcome of triple negative primary breast cancer in older women - comparison with their younger counterparts. (2014)
Journal Article

Triple negative (ER, PgR and HER2 negative) breast cancers (TNBCs) are often considered as a poor prognostic phenotype. There is dearth of evidence showing the prevalence and biological behaviour of TNBCs in older women. This study aimed to analyse t... Read More about Biological characteristics and clinical outcome of triple negative primary breast cancer in older women - comparison with their younger counterparts..